BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 05, 2011
 |  BC Week In Review  |  Company News  |  Deals

Exelixis deal

Exelixis partnered with the National Cancer Institute's Cancer Therapy Evaluation Program (CTEP) for the clinical development of Exelixis' cabozantinib in several types of solid tumors. Exelixis and NCI will conduct up to 20 clinical trials per year in multiple cancers to evaluate safety and...

Read the full 210 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >